KALA BIO Receives Nasdaq Notice on Listing Compliance

KALA BIO ( (KALA) ) just unveiled an announcement.

On January 20, 2026, Kala Bio disclosed that it had received a notice from Nasdaq stating that, based on the company’s closing bid prices between December 3, 2025 and January 16, 2026, its shares had traded below the $1.00 minimum required for continued listing on the Nasdaq Capital Market. The company has been granted a 180-day compliance period, until July 20, 2026, to restore its share price to at least $1.00 for ten consecutive business days, with the possibility of an additional 180-day extension if it meets other listing criteria and commits to a remedy such as a reverse stock split; failure to regain compliance could ultimately lead to delisting, although the notice does not immediately affect trading of the shares.

The most recent analyst rating on (KALA) stock is a Sell with a $0.58 price target. To see the full list of analyst forecasts on KALA BIO stock, see the KALA Stock Forecast page.

Spark’s Take on KALA Stock

According to Spark, TipRanks’ AI Analyst, KALA is a Neutral.

The score is primarily weighed down by weak financial performance (minimal revenue, large losses, heavy cash burn, and negative equity) and bearish technicals (below key moving averages with negative MACD). Corporate events are mixed—debt overhang reduction helps, but Nasdaq compliance and prior distressed developments keep risk elevated; valuation signals are limited due to negative earnings and no dividend.

To see Spark’s full report on KALA stock, click here.

More about KALA BIO

Kala Bio, Inc. is a publicly traded biotechnology company whose common stock is listed on the Nasdaq Capital Market, giving it access to public equity markets and subjecting it to Nasdaq’s continued listing standards, including minimum bid price requirements.

Average Trading Volume: 8,068,695

Technical Sentiment Signal: Sell

Current Market Cap: $16.78M

See more insights into KALA stock on TipRanks’ Stock Analysis page.